Injectable Drug Delivery Market - Global Forecast To 2029
| 出版年月 | 2024年5月 |
| ページ数 | 387 |
| 図表数 | 475 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global Injectable drug delivery market is projected to reach USD 1139.4 billion by 2029 from USD 754.5 billion in 2024, at a CAGR of 8.6% from 2024 to 2029. The increased prevalence of chronic diseases such as diabetes, cancer, autoimmune disorders, and cardiovascular disease needs the development of more effective and tailored medication delivery strategies. Injectable drug delivery systems enable precision dosing and tailored distribution, which improves treatment outcomes.
The growing usage of biologics, such as monoclonal antibodies, peptides, and nucleic acid-based therapies, has increased the need for injectable delivery systems. These big compounds frequently have low oral bioavailability and require parenteral treatment for efficient distribution.
“The Formulations segmented accounted for the largest share during the forecast period.”
Injectable medication formulations are utilized for a variety of therapeutic purposes, including oncology, diabetes, autoimmune illnesses, cardiovascular disease, infectious diseases, and neurological disorders. The adaptability of injectable formulations enables the delivery of a wide range of medications, including small molecules, biologics, peptides, and vaccines, which contributes to their widespread use. Injectable formulations work with a variety of drug delivery devices, such as prefilled syringes, vials, ampoules, cartridges, autoinjectors, pen injectors, and infusion pumps. These delivery systems increase market demand for injectable drug formulations by providing ease of use, accurate dosing, precise administration, and patient convenience. The growing usage of biologic pharmaceuticals and monoclonal antibodies in healthcare has driven up demand for injectable medication formulations. Biologics sometimes require parenteral delivery due to their high molecular size, vulnerability to enzymatic breakdown, and low oral bioavailability. Injectable formulations allow biologics to be administered subcutaneously or intramuscularly, resulting in optimal drug delivery and therapeutic efficacy.
“The ampoules segment accounts for the largest segment in formulation packaging segment.”
Ampoules are hermetically sealed glass containers that provide an effective barrier to contamination, moisture, and air, maintaining the sterility and stability of the medication inside. The sealed form of ampoules inhibits microbial development and degradation of the therapeutic product, lowering the risk of infection and conserving the medication’s integrity until usage.Glass ampoules provide good protection against light and air, which can damage and destabilize certain drugs over time. The opaque quality of glass limits light exposure, while the hermetic barrier prevents oxygen entrance, ensuring that light-sensitive and oxygen-sensitive medications retain their potency and efficacy.
“By Therapeutic application Infectious diseases accounted for the largest share during the forecast period.”
Injectable drug administration is essential for treating a wide range of infectious disorders, including bacterial, viral, fungal, and parasitic infections. Many antibiotics, antiviral treatments, antifungal agents, and antiparasitic medications are given as injections to achieve quick and effective drug concentrations in the bloodstream and target tissues. Injectable drugs are widely used to treat chronic infectious disorders like tuberculosis (TB) and HIV/AIDS. To efficiently target the TB germs and prevent medication resistance, TB treatment frequently combines oral antibiotics with injectable treatments such as rifampin, isoniazid, and streptomycin. Similarly, injectable antiretroviral medications can be used in HIV/AIDS therapy regimens to reduce viral replication and prevent disease progression.
“APAC is estimated to register the highest CAGR during the forecast period.”
The Injectable drug delivery market is divided into Five regions- North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The Asia Pacific is witnessed to have the highest CAGR during the forecast period.. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. Older persons have a higher prevalence of chronic diseases and complex healthcare needs, which drives the demand for injectable drugs for ailments like diabetes, cardiovascular disease, and cancer.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW(16%)
List of Companies Profiled in the Report
o Becton, Dickinson and Company (U.S.),
o Pfizer Inc. (U.S.),
o Teva Pharmaceuticals Industries Ltd. (Israel),
o Eli Lilly and Company (U.S.),
o Baxter International, Inc. (U.S.),
o Sandoz (Germany),
o Terumo (Japan),
o Schott AG (Germany),
o Gerresheimer (Germany),
o Ypsomed (Switzerland),
o Bespak (U.K.), and
o B. Braun Melsungen (Germany).
Research Coverage
This report studies the Injectable drug delivery market based on type, formulation packaging, site of administration, route of administration, facility of use, distribution channels and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total apheresis market. The report forecasts the revenue of the market segments to five major regions.
Reasons to Buy the Report
This report also includes.
• Analysis of key drivers (increasing chronic diseases, increasing biologics, technological advancements) ,restraints (Infections associated with needle stick injuries), challenges(Other methods of Injectable drug delivery available in the market), opportunities (Increase in the demand of generic medicines and biosimilars) contributing the growth of the Injectable drug delivery market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Injectable drug delivery market.
• Market Development: Comprehensive information on the lucrative emerging markets by type, formulation packaging, by site of administration,facility of use and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the Injectable drug delivery market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Injectable drug delivery market..
Table of Contents
1 INTRODUCTION 51
1.1 STUDY OBJECTIVES 51
1.2 MARKET DEFINITION 51
1.3 INCLUSIONS AND EXCLUSIONS 52
1.4 MARKET SCOPE 53
1.4.1 MARKETS COVERED 53
1.4.2 REGIONAL SEGMENTATION 54
FIGURE 1 REGIONS COVERED 54
1.4.3 YEARS CONSIDERED 54
1.4.4 CURRENCY CONSIDERED 55
1.5 MARKET STAKEHOLDERS 55
1.6 SUMMARY OF CHANGES 55
1.7 RECESSION IMPACT 56
2 RESEARCH METHODOLOGY 57
2.1 RESEARCH DATA 57
FIGURE 2 INJECTABLE DRUG DELIVERY MARKET: RESEARCH DESIGN 57
2.1.1 SECONDARY DATA 58
2.1.1.1 Key secondary sources 59
2.1.2 PRIMARY DATA 59
2.1.2.1 Primary sources 60
2.1.2.2 Key data from primary sources 61
2.1.2.3 Breakdown of primaries 62
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 62
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 62
2.2 MARKET SIZE ESTIMATION 62
FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 63
2.2.1 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH 64
FIGURE 6 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 64
2.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 64
FIGURE 7 INJECTABLE DRUG DELIVERY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 65
2.2.3 APPROACH 3: TOP-DOWN APPROACH 65
FIGURE 8 TOP-DOWN APPROACH 65
2.2.4 APPROACH 2: BOTTOM-UP APPROACH: SUPPLY-SIDE ANALYSIS 66
FIGURE 9 BOTTOM-UP APPROACH 66
2.2.5 APPROACH 4: PRIMARY INTERVIEWS 66
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 68
FIGURE 10 DATA TRIANGULATION METHODOLOGY 68
2.4 MARKET SHARE ASSESSMENT 68
2.5 STUDY ASSUMPTIONS 69
TABLE 1 STUDY ASSUMPTIONS 69
2.6 GROWTH RATE ASSUMPTIONS 69
2.7 RISK ASSESSMENT 69
TABLE 2 RISK ASSESSMENT ANALYSIS 69
2.8 RECESSION IMPACT ANALYSIS 70
3 EXECUTIVE SUMMARY 71
FIGURE 11 INJECTABLE DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 71
FIGURE 12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2024 VS. 2029 (USD BILLION) 72
FIGURE 13 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2024 VS. 2029 (USD BILLION) 73
FIGURE 14 GEOGRAPHIC SNAPSHOT OF INJECTABLE DRUG DELIVERY MARKET 74
4 PREMIUM INSIGHTS 75
4.1 INJECTABLE DRUG DELIVERY MARKET OVERVIEW 75
FIGURE 15 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 75
4.2 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE AND COUNTRY (2023) 76
FIGURE 16 FORMULATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 76
4.3 INJECTABLE DRUG DELIVERY DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 77
FIGURE 17 SELF-INJECTION DEVICES SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 77
4.4 INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 78
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 78
5 MARKET OVERVIEW 79
5.1 MARKET DYNAMICS 79
FIGURE 19 INJECTABLE DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 79
5.1.1 DRIVERS 79
5.1.1.1 Rising prevalence of chronic diseases 79
5.1.1.2 Growing demand for self-injection devices 80
5.1.1.3 Growth in biologics market 81
TABLE 3 INDICATIVE LIST OF BIOLOGICS APPROVED BY US FDA (2020) 82
5.1.1.4 Technological advancements in injectable drug delivery products 82
5.1.2 RESTRAINTS 84
5.1.2.1 Infections associated with needlestick injuries 84
5.1.2.2 Higher cost of development compared to conventional injections 85
5.1.3 OPPORTUNITIES 85
5.1.3.1 Increasing demand for biosimilars and generic injectables 85
5.1.3.1.1 Biosimilars 85
5.1.3.1.2 Generic injectables 86
5.1.3.2 Contraceptive injectables 86
5.1.4 CHALLENGES 87
5.1.4.1 Alternative methods of drug delivery 87
5.2 VALUE CHAIN ANALYSIS 87
5.2.1 RESEARCH & DEVELOPMENT 87
5.2.2 PROCUREMENT & PRODUCT DEVELOPMENT 88
5.2.3 MARKETING, SALES & DISTRIBUTION, AND POST-SALES SERVICES 88
FIGURE 20 INJECTABLE DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS 88
5.3 SUPPLY CHAIN ANALYSIS 88
5.3.1 PROMINENT COMPANIES 88
5.3.2 SMALL & MEDIUM-SIZED COMPANIES 88
5.3.3 END USERS 89
FIGURE 21 INJECTABLE DRUG DELIVERY MARKET: SUPPLY CHAIN ANALYSIS 89
5.4 TARIFF AND REGULATORY LANDSCAPE 89
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 4 REGULATORY SCENARIO, BY COUNTRY 89
5.5 TARIFF AND REGULATORY ANALYSIS 92
5.5.1 NORTH AMERICA 92
5.5.1.1 US 92
5.5.1.2 Canada 92
5.5.2 EUROPE 92
5.5.3 ASIA PACIFIC 93
5.5.3.1 China 94
5.5.3.2 Japan 94
5.5.3.3 India 94
5.5.4 LATIN AMERICA 94
5.5.5 MIDDLE EAST 95
5.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 5 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 6 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 7 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 8 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
5.7 ECOSYSTEM ANALYSIS 98
FIGURE 22 INJECTABLE DRUG DELIVERY MARKET: ECOSYSTEM ANALYSIS 98
5.8 TECHNOLOGY ANALYSIS 98
5.8.1 KEY TECHNOLOGIES 98
5.8.2 COMPLEMENTARY TECHNOLOGIES 98
5.8.3 ADJACENT TECHNOLOGIES 99
5.9 PATENT ANALYSIS 99
FIGURE 23 PATENT ANALYSIS FOR INJECTABLE DRUG DELIVERY MARKET (JANUARY 2014–DECEMBER 2023) 99
5.10 KEY CONFERENCES AND EVENTS, 2023–2024 100
TABLE 9 INJECTABLE DRUG DELIVERY MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024 100
5.11 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 100
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 100
5.12 PORTER’S FIVE FORCES ANALYSIS 101
FIGURE 25 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 101
TABLE 10 INJECTABLE DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 101
5.12.1 THREAT OF NEW ENTRANTS 102
5.12.2 THREAT OF SUBSTITUTES 102
5.12.3 BARGAINING POWER OF SUPPLIERS 102
5.12.4 BARGAINING POWER OF BUYERS 102
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 102
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 103
FIGURE 26 KEY STAKEHOLDERS IN BUYING PROCESS 103
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%) 103
5.14 REIMBURSEMENT SCENARIO 103
TABLE 12 REIMBURSEMENT CODES FOR VARIOUS PROCEDURES 103
5.15 UNMET NEEDS IN INJECTABLE DRUG DELIVERY MARKET 104
5.16 INVESTMENT SCENARIO 105
FIGURE 27 NUMBER OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019–2022 105
FIGURE 28 VALUE OF INVESTOR DEALS IN INJECTABLE DRUG DELIVERY MARKET, BY KEY PLAYER, 2019–2022 (USD MILLION) 105
6 INJECTABLE DRUG DELIVERY MARKET, BY TYPE 106
6.1 INTRODUCTION 107
TABLE 13 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 107
6.2 DEVICES 107
TABLE 14 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 108
TABLE 15 INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY REGION, 2021–2029 (USD BILLION) 108
6.2.1 CONVENTIONAL INJECTION DEVICES 109
6.2.1.1 Rising incidence of chronic diseases and low cost of manufacturing to drive market 109
TABLE 16 CONVENTIONAL INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 109
6.2.1.2 By material 109
TABLE 17 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2021–2029 (USD BILLION) 110
6.2.1.2.1 Glass 110
TABLE 18 CONVENTIONAL GLASS INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 110
6.2.1.2.2 Plastic 111
TABLE 19 CONVENTIONAL PLASTIC INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 111
6.2.1.3 By product 111
TABLE 20 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2021–2029 (USD BILLION) 112
6.2.1.3.1 Fillable syringes 112
TABLE 21 FILLABLE SYRINGES MARKET, BY REGION, 2021–2029 (USD BILLION) 112
6.2.1.3.2 Prefilled syringes 112
TABLE 22 PREFILLED SYRINGES MARKET, BY REGION, 2021–2029 (USD BILLION) 113
6.2.1.4 By usability 113
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2021–2029 (USD BILLION) 113
6.2.1.4.1 Reusable injection devices 114
TABLE 24 REUSABLE INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 114
6.2.1.4.2 Disposable injection devices 114
TABLE 25 DISPOSABLE INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 115
6.2.2 SELF-INJECTION DEVICES 115
TABLE 26 SELF-INJECTION DEVICES MARKET, BY TYPE, 2021–2029 (USD BILLION) 116
TABLE 27 SELF-INJECTION DEVICES MARKET, BY REGION, 2021–2029 (USD BILLION) 116
6.2.2.1 Needle-free injectors 116
6.2.2.1.1 Instant and painless administration to boost demand 116
TABLE 28 NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 117
6.2.2.1.2 By product 117
TABLE 29 NEEDLE-FREE INJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION) 117
6.2.2.1.2.1 Fillable needle-free injectors 117
TABLE 30 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 118
6.2.2.1.2.2 Prefilled needle-free injectors 118
TABLE 31 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 118
6.2.2.1.3 By technology 119
TABLE 32 NEEDLE-FREE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD BILLION) 119
6.2.2.1.3.1 Jet-based needle-free injectors 119
TABLE 33 JET-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 120
6.2.2.1.3.2 Spring-based needle-free injectors 120
TABLE 34 SPRING-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 120
6.2.2.1.3.3 Laser-based needle-free injectors 121
TABLE 35 LASER-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 121
6.2.2.1.3.4 Vibration-based needle-free injectors 121
TABLE 36 VIBRATION-BASED NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 121
6.2.2.1.4 By usability 122
TABLE 37 NEEDLE-FREE INJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION) 122
6.2.2.1.4.1 Reusable needle-free injectors 122
TABLE 38 REUSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 122
6.2.2.1.4.2 Disposable needle-free injectors 123
TABLE 39 DISPOSABLE NEEDLE-FREE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 123
6.2.2.2 Autoinjectors 123
6.2.2.2.1 Automated dose delivery to enhance patient care 123
TABLE 40 AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 124
6.2.2.2.2 By product 124
TABLE 41 AUTOINJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION) 124
6.2.2.2.2.1 Fillable autoinjectors 124
TABLE 42 FILLABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 125
6.2.2.2.2.2 Prefilled autoinjectors 125
TABLE 43 PREFILLED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 125
6.2.2.2.3 By technology 126
TABLE 44 AUTOINJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD BILLION) 126
6.2.2.2.3.1 Automated autoinjectors 126
TABLE 45 AUTOMATED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 126
6.2.2.2.3.2 Manual autoinjectors 127
TABLE 46 MANUAL AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 127
6.2.2.2.4 By design 127
TABLE 47 AUTOINJECTORS MARKET, BY DESIGN, 2021–2029 (USD BILLION) 127
6.2.2.2.4.1 Standardized autoinjectors 128
TABLE 48 STANDARDIZED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 128
6.2.2.2.4.2 Customized autoinjectors 128
TABLE 49 CUSTOMIZED AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 129
6.2.2.2.5 By usability 129
TABLE 50 AUTOINJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION) 129
6.2.2.2.5.1 Reusable autoinjectors 129
TABLE 51 REUSABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 130
6.2.2.2.5.2 Disposable autoinjectors 130
TABLE 52 DISPOSABLE AUTOINJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 130
6.2.2.3 Pen injectors 131
6.2.2.3.1 Multi-dose devices that can administer dosage subcutaneously 131
TABLE 53 PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 131
TABLE 54 TABLE COMMERCIALLY AVAILABLE PEN INJECTORS 131
6.2.2.3.2 By product 132
TABLE 55 PEN INJECTORS MARKET, BY PRODUCT, 2021–2029 (USD BILLION) 132
6.2.2.3.2.1 Single-chambered pen injectors 132
TABLE 56 SINGLE-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 132
6.2.2.3.2.2 Dual-chambered pen injectors 133
TABLE 57 DUAL-CHAMBERED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 133
6.2.2.3.3 By design 133
TABLE 58 PEN INJECTORS MARKET, BY DESIGN, 2021–2029 (USD BILLION) 133
6.2.2.3.3.1 Standard pen injectors 134
TABLE 59 STANDARD PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 134
6.2.2.3.3.2 Customized pen injectors 134
TABLE 60 CUSTOMIZED PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 134
6.2.2.3.4 By usability 135
TABLE 61 PEN INJECTORS MARKET, BY USABILITY, 2021–2029 (USD BILLION) 135
6.2.2.3.4.1 Reusable pen injectors 135
TABLE 62 REUSABLE PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 135
6.2.2.3.4.2 Disposable pen injectors 136
TABLE 63 DISPOSABLE PEN INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 136
6.2.2.4 Wearable injectors 136
6.2.2.4.1 High efficacy and enhanced safety to drive market 136
TABLE 64 WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD BILLION) 137
6.2.2.5 Other devices 137
TABLE 65 INJECTABLE DRUG DELIVERY MARKET FOR OTHER DEVICES, BY REGION, 2021–2029 (USD BILLION) 137
6.3 FORMULATIONS 138
TABLE 66 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY TYPE, 2021–2029 (USD BILLION) 138
TABLE 67 INJECTABLE DRUG DELIVERY MARKET FOR FORMULATIONS, BY REGION, 2021–2029 (USD BILLION) 139
6.3.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 139
TABLE 68 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021–2029 (USD BILLION) 139
TABLE 69 CONVENTIONAL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 140
6.3.1.1 Solutions 140
6.3.1.1.1 High stability and sterility benefits to fuel uptake 140
TABLE 70 SOLUTIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 141
6.3.1.2 Reconstituted/lyophilized formulations 141
6.3.1.2.1 Suitable for parenteral administration 141
TABLE 71 RECONSTITUTED/LYOPHILIZED FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 141
6.3.1.3 Suspensions 142
6.3.1.3.1 administered using conventional syringes or cartridges 142
TABLE 72 SUSPENSIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 142
6.3.1.4 Emulsions 142
6.3.1.4.1 Thermodynamic dispersions delivered intravenously 142
TABLE 73 EMULSIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 143
6.3.2 NOVEL DRUG DELIVERY FORMULATIONS 143
TABLE 74 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY TYPE, 2021–2029 (USD BILLION) 144
TABLE 75 NOVEL DRUG DELIVERY FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 144
6.3.2.1 Colloidal dispersions 144
TABLE 76 COLLOIDAL DISPERSIONS MARKET, BY TYPE, 2021–2029 (USD BILLION) 145
TABLE 77 COLLOIDAL DISPERSIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 145
6.3.2.1.1 Niosomes 145
6.3.2.1.1.1 Features include versatility and flexibility 145
TABLE 78 NIOSOMES MARKET, BY REGION, 2021–2029 (USD BILLION) 146
6.3.2.1.2 Liposomes 146
6.3.2.1.2.1 Non-toxic and biocompatible with several indications 146
TABLE 79 LIPOSOMES MARKET, BY REGION, 2021–2029 (USD BILLION) 146
6.3.2.1.3 Polymeric/mixed micelles 147
6.3.2.1.3.1 Ability to deliver hydrophobic drugs with slower dissolution rates 147
TABLE 80 POLYMERIC/MIXED MICELLES MARKET, BY REGION, 2021–2029 USD BILLION) 147
6.3.2.1.4 Nanoparticles 147
TABLE 81 NANOPARTICLES MARKET, BY TYPE, 2021–2029 (USD BILLION) 148
TABLE 82 NANOPARTICLES MARKET, BY REGION, 2021–2029 (USD BILLION) 148
6.3.2.1.4.1 Solid-lipid nanoparticles 148
6.3.2.1.4.1.1 High uptake in parenteral nutrition 148
TABLE 83 SOLID-LIPID NANOPARTICLES MARKET, BY REGION, 2021–2029 (USD BILLION) 149
6.3.2.1.4.2 Nanosuspensions 149
6.3.2.1.4.2.1 Ability to enhance solubility and permeability of drug formulations 149
TABLE 84 NANOSUSPENSIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 149
6.3.2.1.4.3 Nanoemulsions 150
6.3.2.1.4.3.1 Utilized in antibiotic therapy and vaccine delivery 150
TABLE 85 NANOEMULSIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 150
6.3.2.2 Microparticles 150
TABLE 86 MICROPARTICLES MARKET, BY TYPE, 2021–2029 (USD BILLION) 150
6.3.2.2.1 Microspheres 151
6.3.2.2.1.1 Particulate carrier systems with high bioavailability 151
TABLE 87 MICROSPHERES MARKET, BY REGION, 2021–2029 (USD BILLION) 151
6.3.2.2.2 Microcapsules 151
6.3.2.2.2.1 Polymeric excipients with biodegradable features 151
TABLE 88 MICROCAPSULES MARKET, BY REGION, 2021–2029 (USD BILLION) 152
6.3.3 LONG-ACTING INJECTABLE FORMULATIONS 152
6.3.3.1 Advantages include cost efficiency and low side effects 152
TABLE 89 LONG-ACTING INJECTABLE FORMULATIONS MARKET, BY REGION, 2021–2029 (USD BILLION) 152
7 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION 153
7.1 INTRODUCTION 154
TABLE 90 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 154
7.2 AUTOIMMUNE DISEASES 154
TABLE 91 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY TYPE, 2021–2029 (USD BILLION) 155
TABLE 92 INJECTABLE DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD BILLION) 155
7.2.1 RHEUMATOID ARTHRITIS 156
7.2.1.1 Increased focus on early-stage diagnosis and treatment to propel segment growth 156
TABLE 93 INJECTABLE DRUG DELIVERY MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2021–2029 (USD BILLION) 156
7.2.2 MULTIPLE SCLEROSIS 156
7.2.2.1 Increasing target patient pool to drive market 156
TABLE 94 INJECTABLE DRUG DELIVERY MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2021–2029 (USD BILLION) 157
7.2.3 CROHN’S DISEASE 157
7.2.3.1 Increasing use of liposomes to aid segment growth 157
TABLE 95 INJECTABLE DRUG DELIVERY MARKET FOR CROHN’S DISEASE, BY REGION, 2021–2029 (USD BILLION) 158
7.2.4 PSORIASIS 158
7.2.4.1 Lifestyle changes and high disease prevalence to support market growth 158
TABLE 96 INJECTABLE DRUG DELIVERY MARKET FOR PSORIASIS, BY REGION, 2021–2029 (USD BILLION) 159
7.2.5 OTHER AUTOIMMUNE DISEASES 159
TABLE 97 INJECTABLE DRUG DELIVERY MARKET FOR OTHER AUTOIMMUNE DISEASES, BY REGION, 2021–2029 (USD BILLION) 159
7.3 HORMONAL DISORDERS 160
TABLE 98 INJECTABLE DRUG DELIVERY MARKET FOR HORMONAL DISORDERS, BY TYPE, 2021–2029 (USD BILLION) 160
7.3.1 DIABETES 160
7.3.1.1 Growing preference for self-injection devices over traditional syringes to augment market growth 160
TABLE 99 INJECTABLE DRUG DELIVERY MARKET FOR DIABETES, BY REGION, 2021–2029 (USD BILLION) 161
7.3.2 ANEMIA 161
7.3.2.1 Increasing occurrence of nutritional deficiency to drive market 161
TABLE 100 INJECTABLE DRUG DELIVERY MARKET FOR ANEMIA, BY REGION, 2021–2029 (USD BILLION) 162
7.3.3 REPRODUCTIVE HEALTH DISEASES 162
7.3.3.1 Lack of healthcare facilities and hygiene practices to aid market growth 162
TABLE 101 INJECTABLE DRUG DELIVERY MARKET FOR REPRODUCTIVE HEALTH DISEASES, BY REGION, 2021–2029 (USD BILLION) 163
7.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 163
7.3.4.1 High efficacy and safety of heparin for antithrombotic therapy to drive segment 163
TABLE 102 INJECTABLE DRUG DELIVERY MARKET FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY, BY REGION, 2021–2029 (USD BILLION) 163
7.3.5 OSTEOPOROSIS 164
7.3.5.1 Increasing number of women with calcium and vitamin D deficiency to boost segment growth 164
TABLE 103 INJECTABLE DRUG DELIVERY MARKET FOR OSTEOPOROSIS, BY REGION, 2021–2029 (USD BILLION) 164
7.3.6 GROWTH HORMONE DEFICIENCY 164
7.3.6.1 Increased need for daily injections of recombinant human growth hormones to fuel market growth 164
TABLE 104 INJECTABLE DRUG DELIVERY MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021–2029 (USD BILLION) 165
7.4 ORPHAN DISEASES 165
7.4.1 INCREASING NUMBER OF LEGAL AND FINANCIAL INITIATIVES BY GOVERNMENT TO AUGMENT MARKET GROWTH 165
TABLE 105 INJECTABLE DRUG DELIVERY MARKET FOR ORPHAN DISEASES, BY REGION, 2021–2029 (USD BILLION) 165
7.5 CANCER 166
7.5.1 RISING PREVALENCE OF CANCER AND GROWING AVAILABILITY OF THERAPEUTICS TO DRIVE MARKET 166
TABLE 106 INJECTABLE DRUG DELIVERY MARKET FOR CANCER, BY REGION, 2021–2029 (USD BILLION) 166
7.6 INFECTIOUS DISEASES 167
7.6.1 ENVIRONMENTAL CHANGES AND INCREASED MICROBIAL ADAPTATION TO BOOST MARKET GROWTH 167
TABLE 107 INJECTABLE DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2029 (USD BILLION) 167
7.7 OTHER THERAPEUTIC APPLICATIONS 167
TABLE 108 INJECTABLE DRUG DELIVERY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY TYPE, 2021–2029 (USD BILLION) 167
7.7.1 PAIN MANAGEMENT 168
7.7.1.1 Increasing number of new drugs for chronic pain management to aid market growth 168
TABLE 109 INJECTABLE DRUG DELIVERY MARKET FOR PAIN MANAGEMENT, BY REGION, 2021–2029 (USD BILLION) 168
7.7.2 ALLERGIES 169
7.7.2.1 Increasing prevalence of asthma and eczema to drive market 169
TABLE 110 INJECTABLE DRUG DELIVERY MARKET FOR ALLERGIES, BY REGION, 2021–2029 (USD BILLION) 169
7.7.3 AESTHETIC TREATMENTS 170
7.7.3.1 Growing popularity of aesthetic procedures to propel segment growth 170
TABLE 111 INJECTABLE DRUG DELIVERY MARKET FOR AESTHETIC TREATMENTS, BY REGION, 2021–2029 (USD MILLION) 170
7.7.4 HEPATITIS C 171
7.7.4.1 Reuse of injectables and inadequate equipment sterilization to drive market 171
TABLE 112 INJECTABLE DRUG DELIVERY MARKET FOR HEPATITIS C, BY REGION, 2021–2029 (USD BILLION) 171
7.7.5 HEMOPHILIA 171
7.7.5.1 Increasing need for preventive treatment plans to propel segment growth 171
TABLE 113 INJECTABLE DRUG DELIVERY MARKET FOR HEMOPHILIA, BY REGION, 2021–2029 (USD MILLION) 172
8 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING 173
8.1 INTRODUCTION 174
TABLE 114 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 174
8.2 AMPOULES 174
8.2.1 HELPS MAINTAIN STABILITY OF DRUGS, THEREBY ENHANCING EFFICACY 174
TABLE 115 INJECTABLE DRUG DELIVERY MARKET FOR AMPOULES, BY REGION, 2021–2029 (USD BILLION) 175
8.3 VIALS 175
8.3.1 ABILITY TO STORE DRUG FORMULATIONS FOR EXTENSIVE PERIODS 175
TABLE 116 INJECTABLE DRUG DELIVERY MARKET FOR VIALS, BY REGION, 2021–2029 (USD BILLION) 175
8.4 CARTRIDGES 176
8.4.1 OFFERS HIGHER DOSE ACCURACY AND PATIENT CONVENIENCE 176
TABLE 117 INJECTABLE DRUG DELIVERY MARKET FOR CARTRIDGES, BY REGION, 2021–2029 (USD BILLION) 176
8.5 BOTTLES 176
8.5.1 STORAGE OF SOLUTIONS AND EMULSIONS 176
TABLE 118 INJECTABLE DRUG DELIVERY MARKET FOR BOTTLES, BY REGION, 2021–2029 (USD BILLION) 177
9 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN 178
9.1 INTRODUCTION 179
TABLE 119 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 179
9.2 CURATIVE CARE 179
9.2.1 ADMINISTRATION OF THERAPEUTIC MEDICATIONS FOR EARLY DISEASE DETECTION TO PROPEL MARKET 179
TABLE 120 INJECTABLE DRUG DELIVERY MARKET FOR CURATIVE CARE, BY REGION, 2021–2029 (USD BILLION) 180
9.3 IMMUNIZATION 180
9.3.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND 180
TABLE 121 INJECTABLE DRUG DELIVERY MARKET FOR IMMUNIZATION, BY REGION, 2021–2029 (USD BILLION) 181
9.4 OTHER USAGE PATTERNS 181
TABLE 122 INJECTABLE DRUG DELIVERY MARKET FOR OTHER USAGE PATTERNS, BY REGION, 2021–2029 (USD BILLION) 182
10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION 183
10.1 INTRODUCTION 184
TABLE 123 TABLE 1: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 184
10.2 SKIN-BASED ADMINISTRATION 184
10.2.1 RAPID & EFFECTIVE METHOD WITH LOW PAIN TO DRIVE MARKET 184
TABLE 124 INJECTABLE DRUG DELIVERY MARKET FOR SKIN-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION) 185
10.3 CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION 185
10.3.1 HIGH PREFERENCE FOR EMERGENCY CARE TO SUPPORT MARKET GROWTH 185
TABLE 125 INJECTABLE DRUG DELIVERY MARKET FOR CIRCULATORY/MUSCULOSKELETAL-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION) 186
10.4 ORGAN-BASED ADMINISTRATION 186
10.4.1 UTILIZATION OF INTRAVITREAL AND INTRA-OCULAR INJECTIONS IN COMPLEX PROCEDURES TO BOOST DEMAND 186
TABLE 126 INJECTABLE DRUG DELIVERY MARKET BY ORGAN-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION) 187
10.5 CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION 187
10.5.1 ADOPTION OF MIS TECHNIQUES TO DRIVE MARKET 187
TABLE 127 INJECTABLE DRUG DELIVERY MARKET FOR CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION, BY REGION, 2021–2029 (USD BILLION) 187
11 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL 188
11.1 INTRODUCTION 189
TABLE 128 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 189
11.2 HOSPITALS 189
11.2.1 HIGH UPTAKE OF ADVANCED DRUG FORMULATIONS TO DRIVE MARKET 189
TABLE 129 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS, BY REGION, 2021–2029 (USD BILLION) 190
11.3 RETAIL PHARMACY STORES 190
11.3.1 SALE OF OTC AND PRESCRIPTION DRUGS TO SUPPORT MARKET GROWTH 190
TABLE 130 INJECTABLE DRUG DELIVERY MARKET FOR RETAIL PHARMACY STORES, BY REGION, 2021–2029 (USD BILLION) 190
12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS 191
12.1 INTRODUCTION 192
TABLE 131 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 192
12.2 HOSPITALS AND CLINICS 192
12.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 192
TABLE 132 INJECTABLE DRUG DELIVERY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021–2029 (USD BILLION) 193
12.3 HOME CARE SETTINGS 193
12.3.1 GROWING TREND OF SELF-ADMINISTRATION TO PROPEL MARKET 193
TABLE 133 INJECTABLE DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY REGION, 2021–2029 (USD BILLION) 194
12.4 OTHER PATIENT CARE SETTINGS 194
TABLE 134 INJECTABLE DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE, BY REGION, 2021–2029 (USD BILLION) 194
13 INJECTABLE DRUG DELIVERY MARKET, BY REGION 195
13.1 INTRODUCTION 196
13.1.1 NORTH AMERICA: RECESSION IMPACT 196
TABLE 135 INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021–2029 (USD BILLION) 196
13.2 NORTH AMERICA 197
FIGURE 29 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT 198
TABLE 136 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION) 199
TABLE 137 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 199
TABLE 138 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 199
TABLE 139 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 200
TABLE 140 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 200
TABLE 141 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 201
TABLE 142 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 201
TABLE 143 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 202
TABLE 144 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 202
13.2.1 US 202
13.2.1.1 US to command largest share in North American injectable drug delivery market during forecast period 202
TABLE 145 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 203
TABLE 146 US: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 203
TABLE 147 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 204
TABLE 148 US: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 204
TABLE 149 US: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 205
TABLE 150 US: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 205
TABLE 151 US: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 206
TABLE 152 US: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 206
TABLE 153 US: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 206
13.2.2 CANADA 207
13.2.2.1 Increasing government support and rising incidence of chronic diseases to drive market 207
TABLE 154 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 208
TABLE 155 CANADA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 208
TABLE 156 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 208
TABLE 157 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 209
TABLE 158 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 209
TABLE 159 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 210
TABLE 160 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 210
TABLE 161 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 211
TABLE 162 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 211
13.3 EUROPE 211
13.3.1 EUROPE: RECESSION IMPACT 212
TABLE 163 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION) 212
TABLE 164 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 212
TABLE 165 EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 213
TABLE 166 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 213
TABLE 167 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 214
TABLE 168 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 214
TABLE 169 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 215
TABLE 170 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 215
TABLE 171 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 216
TABLE 172 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 216
13.3.2 GERMANY 216
13.3.2.1 High healthcare expenditure and increased focus on pharmaceutical R&D to drive market 216
TABLE 173 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 217
TABLE 174 GERMANY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 217
TABLE 175 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 217
TABLE 176 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 218
TABLE 177 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 218
TABLE 178 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 219
TABLE 179 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 219
TABLE 180 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 220
TABLE 181 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 220
13.3.3 FRANCE 220
13.3.3.1 Increasing geriatric population and rising incidence of autoimmune diseases to spur market growth 220
TABLE 182 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 221
TABLE 183 FRANCE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 221
TABLE 184 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 221
TABLE 185 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 222
TABLE 186 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 222
TABLE 187 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 223
TABLE 188 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 223
TABLE 189 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 224
TABLE 190 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 224
13.3.4 UK 224
13.3.4.1 Growing adoption of generics and increasing collaborations between government and private bodies to aid market growth 224
TABLE 191 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 225
TABLE 192 UK: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 226
TABLE 193 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 226
TABLE 194 UK: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 227
TABLE 195 UK: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 227
TABLE 196 UK: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 228
TABLE 197 UK: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 228
TABLE 198 UK: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 229
TABLE 199 UK: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 229
13.3.5 ITALY 229
13.3.5.1 Low healthcare expenditure and economic downturn to limit market growth 229
TABLE 200 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 230
TABLE 201 ITALY: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD MILLION) 230
TABLE 202 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 230
TABLE 203 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 231
TABLE 204 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 231
TABLE 205 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 232
TABLE 206 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 232
TABLE 207 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 233
TABLE 208 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 233
13.3.6 SPAIN 233
13.3.6.1 Increasing number of mergers and acquisitions to support market growth 233
TABLE 209 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 234
TABLE 210 SPAIN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD MILLION) 234
TABLE 211 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 234
TABLE 212 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 235
TABLE 213 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 235
TABLE 214 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 236
TABLE 215 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 236
TABLE 216 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 237
TABLE 217 SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 237
13.3.7 REST OF EUROPE 237
TABLE 218 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 238
TABLE 219 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 238
TABLE 220 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 238
TABLE 221 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 239
TABLE 222 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 239
TABLE 223 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 240
TABLE 224 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 240
TABLE 225 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 241
TABLE 226 REST OF EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 241
13.4 ASIA PACIFIC 242
13.4.1 ASIA PACIFIC: RECESSION IMPACT 242
FIGURE 30 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET SNAPSHOT 243
TABLE 227 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION) 244
TABLE 228 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 244
TABLE 229 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 244
TABLE 230 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 245
TABLE 231 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 245
TABLE 232 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 246
TABLE 233 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 246
TABLE 234 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 246
TABLE 235 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 247
TABLE 236 ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 247
13.4.2 CHINA 247
13.4.2.1 Rising prevalence of chronic diseases to augment market growth 247
TABLE 237 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 248
TABLE 238 CHINA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 248
TABLE 239 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 248
TABLE 240 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 249
TABLE 241 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 249
TABLE 242 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 250
TABLE 243 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 250
TABLE 244 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 251
TABLE 245 CHINA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 251
13.4.3 JAPAN 251
13.4.3.1 Growing geriatric population and rising demand for self-injections to drive market 251
TABLE 246 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 252
TABLE 247 JAPAN: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 252
TABLE 248 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 252
TABLE 249 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 253
TABLE 250 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 253
TABLE 251 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 254
TABLE 252 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 254
TABLE 253 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 255
TABLE 254 JAPAN: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 255
13.4.4 INDIA 255
13.4.4.1 High incidence of cancer and increased adoption of biosimilars to fuel market growth 255
TABLE 255 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 256
TABLE 256 INDIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 256
TABLE 257 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 257
TABLE 258 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 257
TABLE 259 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 258
TABLE 260 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 258
TABLE 261 INDIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 259
13.4.5 AUSTRALIA 259
13.4.5.1 Increase in R&D funding and favorable taxation policies to fuel market growth 259
TABLE 262 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 259
TABLE 263 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 260
TABLE 264 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 260
TABLE 265 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 261
TABLE 266 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 261
TABLE 267 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 262
TABLE 268 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 262
TABLE 269 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 263
TABLE 270 AUSTRALIA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 263
13.4.6 SOUTH KOREA 263
13.4.6.1 Increasing focus on aesthetic injectable treatments to drive market 263
TABLE 271 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 264
TABLE 272 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 264
TABLE 273 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 264
TABLE 274 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 265
TABLE 275 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 265
TABLE 276 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 266
TABLE 277 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 266
TABLE 278 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 267
TABLE 279 SOUTH KOREA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 267
13.4.7 REST OF ASIA PACIFIC 267
TABLE 280 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 268
TABLE 281 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 268
TABLE 282 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 268
TABLE 283 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 269
TABLE 284 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 269
TABLE 285 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 270
TABLE 286 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 270
TABLE 287 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 271
TABLE 288 REST OF ASIA PACIFIC: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 271
13.5 LATIN AMERICA 272
13.5.1 LATIN AMERICA: RECESSION IMPACT 272
TABLE 289 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2021–2029 (USD BILLION) 273
TABLE 290 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 273
TABLE 291 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 273
TABLE 292 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 274
TABLE 293 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 274
TABLE 294 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 275
TABLE 295 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 275
TABLE 296 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 276
TABLE 297 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 276
TABLE 298 LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 276
13.5.2 BRAZIL 277
13.5.2.1 Increasing obesity and rising incidence of chronic diseases to augment market growth 277
TABLE 299 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 277
TABLE 300 BRAZIL: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 277
TABLE 301 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 278
TABLE 302 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 278
TABLE 303 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 279
TABLE 304 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 279
TABLE 305 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 280
TABLE 306 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 280
TABLE 307 BRAZIL: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 280
13.5.3 MEXICO 281
13.5.3.1 Growing medical tourism and increasing focus of government on healthcare to propel market 281
TABLE 308 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 281
TABLE 309 MEXICO: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 281
TABLE 310 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 282
TABLE 311 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 282
TABLE 312 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 283
TABLE 313 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 283
TABLE 314 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 284
TABLE 315 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 284
TABLE 316 MEXICO: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 284
13.5.4 REST OF LATIN AMERICA 285
TABLE 317 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 285
TABLE 318 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 285
TABLE 319 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 286
TABLE 320 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 286
TABLE 321 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 287
TABLE 322 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 287
TABLE 323 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 288
TABLE 324 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 288
TABLE 325 REST OF LATIN AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 288
13.6 MIDDLE EAST & AFRICA 289
13.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 289
TABLE 326 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY REGION, 2021–2029 (USD BILLION) 290
TABLE 327 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 290
TABLE 328 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 290
TABLE 329 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 291
TABLE 330 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 291
TABLE 331 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 292
TABLE 332 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 292
TABLE 333 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 293
TABLE 334 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 293
TABLE 335 MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 293
13.6.2 GCC COUNTRIES 294
13.6.2.1 Increasing healthcare expenditure to drive market 294
TABLE 336 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 294
TABLE 337 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 294
TABLE 338 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 295
TABLE 339 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 295
TABLE 340 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 296
TABLE 341 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 296
TABLE 342 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 296
TABLE 343 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 297
TABLE 344 GCC COUNTRIES: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 297
13.6.3 REST OF MIDDLE EAST & AFRICA 297
TABLE 345 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2021–2029 (USD BILLION) 298
TABLE 346 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET FOR DEVICES, BY TYPE, 2021–2029 (USD BILLION) 298
TABLE 347 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION, 2021–2029 (USD BILLION) 298
TABLE 348 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION, 2021–2029 (USD BILLION) 299
TABLE 349 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN, 2021–2029 (USD BILLION) 299
TABLE 350 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION, 2021–2029 (USD BILLION) 300
TABLE 351 REST OF MIDDLE EAST AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTINGS, 2021–2029 (USD BILLION) 300
TABLE 352 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING, 2021–2029 (USD BILLION) 301
TABLE 353 REST OF MIDDLE EAST & AFRICA: INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, 2021–2029 (USD BILLION) 301
14 COMPETITIVE LANDSCAPE 302
14.1 OVERVIEW 302
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 302
FIGURE 31 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 302
14.3 REVENUE ANALYSIS 303
FIGURE 32 SEGMENTAL REVENUE ANALYSIS FOR KEY PLAYERS, 2020−2023 (USD MILLION) 303
14.4 MARKET SHARE ANALYSIS 304
FIGURE 33 INJECTABLE DRUG DELIVERY MARKET SHARE ANALYSIS, BY KEY PLAYER (2023) 304
TABLE 354 INJECTABLE DRUG DELIVERY MARKET: DEGREE OF COMPETITION 305
14.5 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS, 2023 305
14.5.1 STARS 305
14.5.2 EMERGING LEADERS 305
14.5.3 PERVASIVE PLAYERS 306
14.5.4 PARTICIPANTS 306
FIGURE 34 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023) 306
14.5.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023) 307
TABLE 355 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023) 307
TABLE 356 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023) 307
TABLE 357 USAGE PATTERN: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (2023) 308
TABLE 358 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023) 309
TABLE 359 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS (2023) 310
FIGURE 35 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 311
14.6 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 311
14.6.1 STARS 311
14.6.2 EMERGING LEADERS 311
14.6.3 PERVASIVE PLAYERS 312
14.6.4 PARTICIPANTS 312
FIGURE 36 COMPANY EVALUATION MATRIX: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 312
14.6.5 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 313
TABLE 360 FORMULATION PACKAGING: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023) 313
TABLE 361 THERAPEUTIC APPLICATIONS: INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS (2023) 313
TABLE 362 USAGE PATTERN: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 314
TABLE 363 SITE OF ADMINISTRATION: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 315
TABLE 364 REGION FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (2023) 315
FIGURE 37 COMPANY FOOTPRINT: INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS 316
14.6.6 COMPANY BENCHMARKING 316
TABLE 365 INJECTABLE DRUG DELIVERY MANUFACTURERS MARKET 316
14.7 COMPANY VALUATION AND FINANCIAL METRICS 317
FIGURE 38 EV/EBITDA OF KEY VENDORS 317
FIGURE 39 5-YEAR STOCK BETA OF KEY VENDORS 317
14.8 PRODUCT/BRAND COMPARISON 318
FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY TYPE (2023) 318
14.9 COMPETITIVE SCENARIO 319
14.9.1 PRODUCT LAUNCHES & APPROVALS 319
TABLE 366 INJECTABLE DRUG DELIVERY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024 319
14.9.2 DEALS 321
TABLE 367 INJECTABLE DRUG DELIVERY MARKET: DEALS, JANUARY 2021– MARCH 2024 321
15 COMPANY PROFILES 322
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
15.1 INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS 322
15.1.1 BECTON, DICKINSON AND COMPANY 322
TABLE 368 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 322
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 323
TABLE 369 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 323
TABLE 370 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS 326
TABLE 371 BECTON, DICKINSON AND COMPANY: DEALS 326
TABLE 372 BECTON, DICKINSON AND COMPANY: EXPANSIONS 327
15.1.2 PFIZER, INC. 328
TABLE 373 PFIZER, INC.: COMPANY OVERVIEW 328
FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2023) 329
TABLE 374 PFIZER, INC.: PRODUCTS OFFERED 329
TABLE 375 PFIZER, INC.: PRODUCT APPROVALS 336
TABLE 376 PFIZER, INC.: DEALS 337
15.1.3 JOHNSON & JOHNSON SERVICES, INC. 338
TABLE 377 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 338
FIGURE 43 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022) 339
TABLE 378 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 339
TABLE 379 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT LAUNCHES & APPROVALS 347
TABLE 380 JOHNSON & JOHNSON SERVICES, INC.: DEALS 348
15.1.4 SANDOZ GROUP AG 350
TABLE 381 SANDOZ GROUP AG: COMPANY OVERVIEW 350
FIGURE 44 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023) 351
TABLE 382 SANDOZ GROUP AG: PRODUCTS OFFERED 351
TABLE 383 SANDOZ GROUP AG: PRODUCT LAUNCHES & APPROVALS 352
TABLE 384 SANDOZ GROUP AG: DEALS 352
15.1.5 MERCK& CO., INC. 353
TABLE 385 MERCK & CO. INC.: COMPANY OVERVIEW 353
FIGURE 45 MERCK & CO., INC.: COMPANY SNAPSHOT (2022) 354
TABLE 386 MERCK & CO., INC.: PRODUCTS OFFERED 354
TABLE 387 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS 359
TABLE 388 MERCK & CO., INC.: DEALS 359
15.1.6 GLAXOSMITHKLINE PLC 360
TABLE 389 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 360
FIGURE 46 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022) 361
TABLE 390 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 361
TABLE 391 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS 365
TABLE 392 GLAXOSMITHKLINE PLC: DEALS 366
TABLE 393 GLAXOSMITHKLINE PLC: EXPANSIONS 368
15.1.7 TEVA PHARMACEUTICAL INDUSTRIES LTD. 369
TABLE 394 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 369
FIGURE 47 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023) 370
TABLE 395 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 370
TABLE 396 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES & APPROVALS 371
TABLE 397 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS 373
15.1.8 ELI LILLY AND COMPANY 374
TABLE 398 ELI LILLY AND COMPANY: COMPANY OVERVIEW 374
FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022) 375
TABLE 399 ELI LILLY AND COMPANY: PRODUCTS OFFERED 375
TABLE 400 ELI LILLY AND COMPANY: PRODUCTS LAUNCHES & APPROVALS 376
TABLE 401 ELI LILLY AND COMPANY: DEALS 377
TABLE 402 ELI LILLY AND COMPANY: EXPANSIONS 377
15.1.9 SUN PHARMACEUTICAL INDUSTRIES LTD. 378
TABLE 403 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 378
TABLE 404 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 378
TABLE 405 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS 379
TABLE 406 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS 379
15.1.10 BAXTER INTERNATIONAL, INC. 380
TABLE 407 BAXTER INTERNATIONAL, INC.: COMPANY OVERVIEW 380
FIGURE 49 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022) 381
TABLE 408 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED 381
TABLE 409 BAXTER INTERNATIONAL, INC.: PRODUCT APPROVALS 382
15.1.11 GERRESHEIMER AG 383
TABLE 410 GERRESHEIMER AG: COMPANY OVERVIEW 383
FIGURE 50 GERRESHEIMER AG: COMPANY SNAPSHOT (2022) 384
TABLE 411 GERRESHEIMER AG: PRODUCTS OFFERED 384
TABLE 412 GERRESHEIMER AG: PRODUCT LAUNCHES 385
TABLE 413 GERRESHMEIMER AG: DEALS 385
15.1.12 SCHOTT PHARMA 386
TABLE 414 SCHOTT PHARMA: COMPANY OVERVIEW 386
FIGURE 51 SCHOTT AG: COMPANY SNAPSHOT (2022) 386
TABLE 415 SCHOTT PHARMA: PRODUCTS OFFERED 387
TABLE 416 EXPANSIONS 388
15.2 INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS 389
15.2.1 TERUMO CORPORATION 389
TABLE 417 TERUMO CORPORATION: COMPANY OVERVIEW 389
FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT (2022) 390
TABLE 418 TERUMO CORPORATION: PRODUCTS OFFERED 390
TABLE 419 PRODUCT LAUNCHES & APPROVALS 391
15.2.2 ANTARES PHARMA, INC. 392
TABLE 420 ANTARES PHARMA, INC.: COMPANY OVERVIEW 392
15.2.3 B. BRAUN MELSUNGEN AG 393
TABLE 421 B. BRAUN MELSUNGEN AG: COMPANY OVERVIEW 393
15.2.4 SMITHS MEDICAL 394
TABLE 422 SMITHS MEDICAL: COMPANY OVERVIEW 394
15.2.5 FRESENIUS KABI AG 395
TABLE 423 FRESENIUS KABI AG: COMPANY OVERVIEW 395
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
16 APPENDIX 396
16.1 DISCUSSION GUIDE 396
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 400
16.3 RELATED REPORTS 402
16.4 AUTHOR DETAILS 403
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11